Weld Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Weld Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-3,607	Closed	-$360K	–	549
2020 Q1	$360K	Buy	+3,607	New	+$466K	0.18%	206
2019 Q4	–	Sell	-2,888	Closed	-$370K	–	770
2019 Q3	$370K	Buy	+2,888	New	+$387K	0.07%	493
2019 Q1	–	Sell	-3,533	Closed	-$438K	–	766
2018 Q4	$438K	Buy	+3,533	New	+$524K	0.1%	395

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Weld Capital Management's JAZZ Position: Q2 2020 in Review

Weld Capital Management sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2020, closing a stake of 3,607 shares — an estimated $360K sold.

Weld Capital Management first reported a position in JAZZ in Q4 2018 and held it in 3 quarters. The position peaked at $438K in Q4 2018. 384 funds tracked by Wall St. Rank hold JAZZ as of Q2 2020.

Weld Capital Management reported no remaining Jazz Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Weld Capital Management sold 3,607 Jazz Pharmaceuticals shares in Q2 2020, an estimated $360K.
Weld Capital Management first reported a position in Jazz Pharmaceuticals in Q4 2018 and held it in 3 quarters.
Weld Capital Management's Jazz Pharmaceuticals position peaked at $438K in Q4 2018.
384 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2020.

Based on Weld Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.